Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 10, 2007, Pages 1561-1567

  Park, Seog Yun ^a   Kim, Baek Hee ^a   Kim, Jung Ho ^a   Lee, Sun ^b   Kang, Gyeong Hoon ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CELL PROTEIN; CYTOKERATIN 20; CYTOKERATIN 7; ESTROGEN RECEPTOR; GROSS CYSTIC DISEASE FLUID PROTEIN 15; MUCIN 2; MUCIN 5AC; SMAD4 PROTEIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; BILE DUCT CARCINOMA; BREAST CARCINOMA; CANCER LOCALIZATION; CLINICAL FEATURE; COLORECTAL CARCINOMA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; PANCREAS CARCINOMA; PHENOTYPE; PREDICTION; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STOMACH CARCINOMA; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; VALIDATION STUDY;

ADENOCARCINOMA; DECISION TREES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; NEOPLASMS, UNKNOWN PRIMARY; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 35348931111     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005.
2. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.
3. Brown RW, Campagna LB, Dunn JK, Cagle PT. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: a diagnostic adjunct in the determination of primary site. Am J Clin Pathol. 1997;107:12-19.
4. Hammar SP. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol. 1998;29:1393-1402.
5. Bai YQ, Yamamoto H, Akiyama Y, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett. 2002;176:47-55.
6. Johansson L. Histopathologic classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol. 2004;8:259-267.
7. Levine PH, Joutovsky A, Cangiarella J, Yee H, Simsir A. CDX-2 expression in pulmonary fine-needle aspiration specimens: a useful adjunct for the diagnosis of metastatic colorectal adenocarcinoma. Diagn Cytopathol. 2006;34:191-195.
8. Moldvay J, Jackel M, Bogos K, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res. 2004;10:85-88.
9. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310.
10. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002;26:767-773.
11. Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer CJ. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol. 1998;29:491-497.
12. Rubin BP, Skarin AT, Pisick E, Rizk M, Salgia R. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001;10:77-82.
13. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer. 2002;38:758-763.
14. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol. 2000;17:184-193.
15. Kaufmann O, Deidesheimer T, Muehlenberg M, Deicke P, Dietel M. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology. 1996;29:233-240.
16. Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005;29:1482-1489.
17. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res. 1996;56:2527-2530.
18. Baker PM, Oliva E. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int J Gynecol Pathol. 2005;24:39-55.
19. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol. 2002;21:391-400.
20. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun. 2003;306:799-804.
21. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol. 2000;156:37-43.
22. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772.
23. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124:838-845.
24. Jhala N, Jhala D, Vickers SM, et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol. 2006;126:572-579.
25. Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg. 2006;141:968-973; discussion 74.
26. Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol. 2000;31:672-677.
27. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol. 2005;29:359-367.
28. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol. 2004;122:61-69.
29. Lee MJ, Lee HS, Kim WH, Choi Y, Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16:403-410.
30. O'Connell FP, Wang HH, Odze RD. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med. 2005;129:338-347.